Literature DB >> 25744244

Downregulation of ABCE1 via siRNA affects the sensitivity of A549 cells against chemotherapeutic agents.

Göknur Kara1, Sema Tuncer, Mustafa Türk, Emir Baki Denkbaş.   

Abstract

ATP-binding cassette E1 (ABCE1) is involved in several biological functions in cancer cells such as tumor proliferation, antiapoptotic pathway and chemoresistance mechanism. This work aimed to investigate the alterations in chemosensitivity of A549 lung cancer cells for 5-Fluorouracil (5-FU) and irinotecan by silencing ABCE1 using specific small interfering RNAs (siRNA). The cells were treated with low doses of drugs, alone and also their combinations with ABCE1 siRNA. Cytotoxicity, cell proliferation and apoptosis/necrosis evaluations were performed in order to examine the effects of the combined treatment. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to confirm the downregulation of ABCE1. We also investigated the levels of B cell lymphoma 2 (Bcl-2) and mammalian target of rapamycin (mTOR) after the treatments by RT-PCR. Downregulation of ABCE1 improved the anticancer effects of 5-FU in inducing cell viability/proliferation inhibition and apoptosis/necrosis, whereas interestingly, almost did not change or slightly reduced the anticancer effects of irinotecan. ABCE1 expression significantly decreased by transfecting the cells with ABCE1 siRNA. Moreover, Bcl-2 and mTOR levels changed after the single or combined therapy in parallel with the apoptotic and antiproliferation effect. In conclusion, the simultaneous treatment of lung cancer cells with ABCE1 siRNA and 5-FU exhibited synergistic or additive effects; however, ABCE1 siRNA and irinotecan had unexpected antagonistic effects. Our findings demonstrate that the strategy of downregulation of ABCE1 may be included in conventional 5-FU chemotherapy for lung cancer, minimizing the usage of 5-FU at high dosages.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25744244     DOI: 10.1007/s12032-015-0557-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  36 in total

1.  Optimization of cytotoxicity assay by real-time, impedance-based cell analysis.

Authors:  G Ramis; L Martínez-Alarcón; J J Quereda; L Mendonça; M J Majado; K Gomez-Coelho; A Mrowiec; J M Herrero-Medrano; J M Abellaneda; F J Pallares; A Ríos; P Ramírez; A Muñoz
Journal:  Biomed Microdevices       Date:  2013-12       Impact factor: 2.838

2.  Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin.

Authors:  Kazushi Suzuki; Toshio Kokuryo; Takeshi Senga; Yukihiro Yokoyama; Masato Nagino; Michinari Hamaguchi
Journal:  Cancer Sci       Date:  2010-01-20       Impact factor: 6.716

3.  A small interfering ABCE1-targeting RNA inhibits the proliferation and invasiveness of small cell lung cancer.

Authors:  Bo Huang; Ying Gao; Dali Tian; Maogen Zheng
Journal:  Int J Mol Med       Date:  2010-05       Impact factor: 4.101

Review 4.  Gene therapy and ovarian cancer: a review.

Authors:  M N Barnes; J S Deshane; M Rosenfeld; G P Siegal; D T Curiel; R D Alvarez
Journal:  Obstet Gynecol       Date:  1997-01       Impact factor: 7.661

5.  Cancer trends and incidence and mortality patterns in Turkey.

Authors:  Hakki Hakan Yılmaz; Nuray Yazıhan; Dilara Tunca; Arzu Sevinç; Emire Özen Olcayto; Nejat Ozgül; Murat Tuncer
Journal:  Jpn J Clin Oncol       Date:  2010-06-17       Impact factor: 3.019

Review 6.  Cancer gene therapy: an awkward adolescence.

Authors:  Michael M Gottesman
Journal:  Cancer Gene Ther       Date:  2003-07       Impact factor: 5.987

Review 7.  5-fluorouracil: a pharmacological paradigm in the use of cytotoxics.

Authors:  D M Thomas; J R Zalcberg
Journal:  Clin Exp Pharmacol Physiol       Date:  1998-11       Impact factor: 2.557

8.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.

Authors:  X H Liu; S Yao; A Kirschenbaum; A C Levine
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

Review 9.  Current strategies in cancer gene therapy.

Authors:  Anas El-Aneed
Journal:  Eur J Pharmacol       Date:  2004-09-13       Impact factor: 4.432

10.  Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy.

Authors:  Yuan Zhang; Lei Peng; Russell J Mumper; Leaf Huang
Journal:  Biomaterials       Date:  2013-08-08       Impact factor: 12.479

View more
  5 in total

1.  Genistein suppresses retinoblastoma cell viability and growth and induces apoptosis by upregulating miR-145 and inhibiting its target ABCE1.

Authors:  Dong Wei; Lieying Yang; Bo Lv; Lijuan Chen
Journal:  Mol Vis       Date:  2017-07-03       Impact factor: 2.367

2.  MicroRNA‑145 promotes the apoptosis of leukemic stem cells and enhances drug‑resistant K562/ADM cell sensitivity to adriamycin via the regulation of ABCE1.

Authors:  Zhijun Wuxiao; Hua Wang; Qunhao Su; Haiyan Zhou; Min Hu; Shi Tao; Lu Xu; Yu Chen; Xinbao Hao
Journal:  Int J Mol Med       Date:  2020-07-15       Impact factor: 4.101

3.  Predicting chemosensitivity using drug perturbed gene dynamics.

Authors:  Joshua D Mannheimer; Ashok Prasad; Daniel L Gustafson
Journal:  BMC Bioinformatics       Date:  2021-01-07       Impact factor: 3.169

4.  Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistance.

Authors:  Ridwan Islam; Juhi Mishra; Navatha Shree Polavaram; Sreyashi Bhattacharya; Zhengdong Hong; Sanika Bodas; Sunandini Sharma; Alyssa Bouska; Tyler Gilbreath; Ahmed M Said; Lynette M Smith; Benjamin A Teply; Michael H Muders; Surinder K Batra; Kaustubh Datta; Samikshan Dutta
Journal:  Cell Rep       Date:  2022-07-19       Impact factor: 9.995

5.  Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.

Authors:  Peng Zhang; Xiao-Bing Chen; Bing-Qian Ding; Hong-Lin Liu; Tao He
Journal:  Biosci Rep       Date:  2018-12-11       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.